Compare BIO-TECHNE Corp (TECH) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Exxon Mobil Corporation — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Exxon Mobil Corporation trades at $164.41 (market cap $660.62B). The key difference: Exxon Mobil Corporation is far larger — about 58.3× BIO-TECHNE Corp's market cap, and Exxon Mobil Corporation pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| TECH | XOM | |
|---|---|---|
Market Cap | $11.34B | $660.62B |
Sector | Health | Energy |
52-Week High | $72.48 | $171.52 |
52-Week Low | $43.31 | $110.64 |
Enterprise Value | $11.36B | $692.40B |
Dividend Yield | 0.44% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
ExxonMobil (XOM) trades at $164.26, up 3.01% today, with a neutral technical signal and bullish moving averages. The stock shows solid profitability with a 9.07% net margin and 12.55% ROE, though revenue and net income have declined from 2022 peaks. Recent earnings beat estimates in two of the last three quarters, with Q3 2026 results pending. Analyst consensus is a $168.14 price target, with 39% buy ratings. News highlights Exxon's Permian Basin strength and warnings of potential oil price spikes to $160.
XOM offers value with a P/E of 20.68 and strong cash flow, but faces risks from volatile oil prices and declining margins. The dividend provides income, yet geopolitical tensions and energy transition pressures pose challenges. Upside depends on execution in the Permian and oil market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
